• 1. Synthesis and properties of cobalt(III) complexes of tripodal ligands containing amide functional groups
  Patricia M. Angus,Anthony J. Elliott,Alan M. Sargeson,Anthony C. Willis J. Chem. Soc. Dalton Trans. 1999 1131
• 2. Selective addition to [60]fullerene of two different radicals generated from Mn(iii)-based radical reaction
  Guan-Wu Wang,Ting-Hu Zhang,Xin Cheng,Fan Wang Org. Biomol. Chem. 2004 2 1160
• 3. Visible-light induced dearomatization reactions
  Yuan-Zheng Cheng,Zuolijun Feng,Xiao Zhang,Shu-Li You Chem. Soc. Rev. 2022 51 2145
• 4. The Mitsunobu reaction in the 21st century
  S. Fletcher Org. Chem. Front. 2015 2 739
• 5. EPR studies of the additon of 1,1-bis(alkoxycarbonyl)alkyl radicals and tris(ethoxycarbonyl)methyl radicals to alkenes and to alkyl isocyanides
  Valérie Diart,Brian P. Roberts J. Chem. Soc. Perkin Trans. 2 1992 1761

• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of Triethyl Methanetricarboxylate (CAS 6279-86-3) in Chemical Biology and Pharmaceutical Research

Triethyl methanetricarboxylate (CAS 6279-86-3) has recently emerged as a versatile building block in medicinal chemistry and chemical biology research. This trifunctional ester compound has gained attention due to its unique reactivity profile that enables diverse molecular transformations. Recent studies have demonstrated its utility in multicomponent reactions, particularly in the synthesis of heterocyclic scaffolds with potential pharmaceutical applications.

A 2023 study published in the Journal of Medicinal Chemistry reported the use of triethyl methanetricarboxylate as a key intermediate in the development of novel kinase inhibitors. The researchers utilized its three ester groups for sequential modifications, creating a library of 127 compounds with varying pharmacophores. This approach yielded several lead compounds showing promising activity against tyrosine kinase receptors implicated in cancer progression.

In the field of prodrug design, a recent breakthrough application was reported in ACS Medicinal Chemistry Letters (2024). Scientists developed a pH-sensitive prodrug system where triethyl methanetricarboxylate served as a biodegradable linker between an anticancer agent and a targeting moiety. The ester groups provided multiple points for controlled release, demonstrating improved tumor specificity and reduced systemic toxicity in preclinical models.

Structural biology studies have also benefited from this compound's properties. A Nature Chemical Biology publication (2023) described its use as a crystallization additive for membrane proteins. The three ester groups were found to interact with hydrophobic protein domains, enhancing crystal formation while maintaining protein stability - a significant advancement for structure-based drug design.

From a synthetic methodology perspective, Green Chemistry (2024) reported an eco-friendly protocol using triethyl methanetricarboxylate in water-mediated reactions. This development addresses growing concerns about solvent waste in pharmaceutical manufacturing, with the added benefit of higher yields (82-95%) compared to traditional organic solvent systems.

Ongoing clinical trials (Phase I/II) are investigating derivatives of triethyl methanetricarboxylate as potential treatments for neurodegenerative diseases. Preliminary results suggest these compounds can cross the blood-brain barrier and exhibit neuroprotective effects, possibly through modulation of mitochondrial function.

The compound's safety profile has been recently reevaluated through comprehensive toxicological studies (Regulatory Toxicology and Pharmacology, 2023). Results confirmed its low acute toxicity (LD50 > 2000 mg/kg in rodents) and minimal genotoxic potential, supporting its continued use in pharmaceutical applications.

Future research directions appear focused on expanding the compound's applications in targeted drug delivery systems and as a scaffold for covalent inhibitor development. Several patent applications filed in 2024 indicate growing commercial interest in its pharmaceutical uses, particularly in oncology and anti-infective therapies.

• 2985-33-3(Ethyl 2-Carboxypropionate)
• 40516-46-9(Propanedioic acid,2-(ethoxymethyl)-, 1,3-diethyl ester)
• 54840-57-2(Diethyl Methyl-D3-malonate)
• 609-08-5(1,3-diethyl 2-methylpropanedioate)
• 33142-25-5(Diethyl -forMylMalonate)
• 68922-87-2(Triethyl Sodium Methanetricarboxylate)
• 16515-90-5(triethyl 1,1,1-ethanetricarboxylate)
• 2917-80-8(malonic acid, dimethyl-, diisobutyl ester)
• 6065-52-7(Propanedioic acid, methyl-, ethyl methyl ester)
• 89329-03-3(Propanedioic acid, (acetyloxy)methyl-, monomethyl ester, (S)-)